Bacterial and Fungal Infections - Kozel Flashcards
What are the general features of Bacillus spa?
- gram pos rods
- areobes and facultative anaerobes
- spore forming
- 200 species
- B. anthraces and B. cereus are clinically important
Name two microbes that are spore forming.
- clostridium spp
2. bacillus spp
Are Bacillus bacteria encapsulated?
Yes. They have a polypeptide capsule (unusual - most are polysaccharide) that provides protection against phagocytosis. This capsule induces protective immunity in the host. Capsule genes are carried on a plasmid.
What toxins does the Bacillus species produce?
- They produce A-B type toxins. The A is the active portion and the B is the binding portion
- The toxin produced has PA or protective antigen, LF or lethal factor OR EF or edema factor
What is protective antigen?
Protective antigen is the binding portion of the A-B toxin produced by the Bacillus species. It binds cellular receptors and facilitates uptake of EF or LF - two other toxins produced by Bacillus. This antigen induces protective immunity.
What is lethal factor?
Lethal factor is an active component of toxin produced by Bacillus. Lethal factor is a protease that produces cell death. It is important in the pathology of inhalation anthrax.
What is Edema factor?
Edema factor is an active component of toxin produced by Bacillus. Edema factor is an adenylate cyclase that produces edema. It is important in the pathology of cutaneous anthrax.
Bacillus anthracis causes several clinical diseases. What are they?
- cutaneous anthrax
- gastrointestinal anthrax
- inhalation anthrax
Describe cutaneous anthrax.
- follows inoculation with B. anthracis spores
- presents with a painless papule that progresses to ulcer and then to a malignant pustule with a necrotic black eschar
- cutaneous form rarely progresses to a systemic form
- often seen with veterinarians due to their animal contact
Describe gastrointestinal anthrax.
- follows ingestion of spores of B. anthracis
- presents with local infection that may spread to systemic disease
- systemic symptoms are flu-like
Describe inhalational anthrax.
- follow inhalation of spores of B. anthracis
- spreads from lungs to regional lymph nodes and then becomes systemic
- causes hypotension, pulmonary edema, massive bacteremia and acute fatal toxic shock
- may have prolonged incubation period
- fatal if untreated
How is B. anthracis infection identified in the laboratory?
- specimen is taken from blood or eschar material
- specimen can be directly examined - gram stain of blood often positive, are gram-pos rods in chains. Capsule can also be stained.
- specimen can be grown on blood agar
- can identify by PCR and other specialized tests
- Bacillus spa are ubiquitous so just growing a culture may not be helpful. The Laboratory Response Network is equipped to test samples for B. anthracis specifically
Describe the epidemiology and control of anthrax.
- primarily a disease of herbivores
- not communicable
- humans normally infected by exposure to animals or animal products - called wool sorter’s disease
- potential for bioterrorism
- vaccine for humans and animals available
What is the vaccine for anthrax called?
- AVA - acellular vaccine adsorbed, has shown efficacy in wool sorter’s disease but has many issues
- animal vaccine is live vaccine
How is anthrax treated?
- main treatment is ciprofloxacin, also doxycycline can be given
- once there is massive toxin production, treatment is ineffective
- there is potential for monoclonal antibodies to protective antigen
- phrophylaxis in exposed individuals - ciprofloxacin or doxycycline for 40 days and vaccination with AVA